Subject
Editions published in Blood Cancer Journal 200
Too many entities requested (1049). Only 200 are displayed.
-
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
-
EZH2 alterations in follicular lymphoma: biological and clinical correlations.
-
Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma
-
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
-
Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma
-
Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients
-
Identification of cell-type-specific mutations in nodal T-cell lymphomas.
-
A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens.
-
The blind men and the AML elephant: can we feel the progress?
-
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
-
Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
-
New investigational drugs with single-agent activity in multiple myeloma
-
The role of maintenance therapy in multiple myeloma
-
'Acute myeloid leukemia: a comprehensive review and 2016 update'
-
CircRNAs in hematopoiesis and hematological malignancies
-
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up
-
MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
-
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
-
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.
-
The complexity of interpreting genomic data in patients with acute myeloid leukemia
-
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
-
RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity
-
PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
-
Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004.
-
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
-
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
-
Karyotype complexity and prognosis in acute myeloid leukemia
-
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
-
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia
-
Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life
-
miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia
-
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
Subject - wd:Q2464036